background: targeting of cd20 antigen with monoclonal antibodies has become the mainstay in the treatment of non-hodgkin's lymphomas and immunotherapeutic depletion of malignant b cells. accessibility of antigen is one of the crucial factors in development of monoclonal antibodies against this antigen. one major problem in expression of full length cd20 is aggregation and misfolding. there...

background: diffuse large b-cell lymphoma (dlbcl) is an aggressive malignancy of mature b lymphocytes. it is known as a heterogeneous disease with variable therapeutic responses and alternative therapies. morphological and immunophenotypical evaluation of the biopsy specimens can help diagnose dlbcl. methods: in the current study, 44 patients were chosen from shaheed sadoghi hospital (2010–2013...

Background: Targeting of CD20 antigen with monoclonal antibodies has become the mainstay in the treatment of non-Hodgkin's lymphomas and immunotherapeutic depletion of malignant B cells. Accessibility of antigen is one of the crucial factors in development of monoclonal antibodies against this antigen. One major problem in expression of full length CD20 is aggregation and misfolding. Therefore,...

ABSTRACT Introduction: Non-Hodgkin lymphoma (NHL) is a cancer that starts in lymphocytes. The main treatment for NHL is chemotherapy and radiation. Today immunotherapy is a promising therapeutic approach in the treatment of a variety cancers which is high specific unlike previous methods. Antibodies do not penetrate effectively into tumore tissues because of their large size. Whe...

PURPOSE The aim of this research was to further investigate the contribution of CD20 antigen expression to rituximab activity and define the mechanisms responsible for CD20 downregulation in rituximab-resistant cell lines (RRCL). EXPERIMENTAL DESIGN Rituximab-sensitive cell lines, RRCL, and primary neoplastic B cells were evaluated by chromium-51 release assays, ImageStream image analysis, im...

Change of CD20 expression was examined in cases of diffuse large B-cell lymphoma (DLBCL). CD20 expression after treatment with anti-CD20 antibody (rituximab, Rx) for DLBCL was examined in 23 cases who received serial biopsy by immunohistochemistry (IHC) and flow cytometry (FCM). CD20- by IHC and/or FCM was defined as CD20-. Four cases were CD20- at initial biopsy but became CD20+ after chemothe...

CD20 plays a role in human B cell proliferation and is an effective target for immunotherapy. In this study, mouse CD20 expression and biochemistry were assessed for the first time using a new panel of CD20-specific mAb, with CD20 function assessed using CD20-deficient (CD20(-/-)) mice. CD20 expression was B cell restricted and was initiated during late pre-B cell development. The frequency and...

Purpose: The aim of this research was to further investigate the contribution of CD20 antigen expression to rituximab activity and define the mechanisms responsible for CD20 downregulation in rituximabresistant cell lines (RRCL). Experimental Design: Rituximab-sensitive cell lines, RRCL, and primary neoplastic B cells were evaluated by chromium-51 release assays, ImageStream image analysis, imm...

CD20 is a plasma membrane phosphoprotein expressed exclusively by B lymphocytes. mAb binding to CD20 alters cell cycle progression and differentiation, indicating that CD20 plays an essential role in B lymphocyte function. Whole-cell patch clamp and fluorescence microscopy measurements of plasma membrane ionic conductance and cytosolic-free Ca2+ activity, respectively, were used to directly exa...

Uses : = Low-grade or follicular CD20-positive non-Hodgkin’s lymphoma = Follicular CD20-positive non-Hodgkin's lymphoma = Low-grade or follicular CD20-positive non-Hodgkin’s lymphoma = CD20-positive diffuse large B-cell non-Hodgkin’s lymphoma = CD20-positive chronic lymphocytic leukemia, Mantle cell lymphoma. = Granulomatosis with Polyangiitis (GPA) (Wegener’s Granulomatosis) and Microscopic Po...